QPPV.COM KNOWLEDGE ASSESSMENT

Drug-Induced Liver Injury (DILI): From Liver Test Abnormalities to Causality and Regulatory Safety Assessment

Test your understanding of the concepts covered by Drug-Induced Liver Injury (DILI): From Liver Test Abnormalities to Causality and Regulatory Safety Assessment.

Question 1 of 10Pass mark: 80%

Question 1 of 10 ALT is 10 times the ULN and ALP is 2 times the ULN at the relevant assessment point. What R-ratio classification follows the conventional approach?

Cholestatic Mixed Hepatocellular Unclassifiable because bilirubin is required to calculate the R-ratio

Question 2 of 10 A trial participant meets commonly used screening thresholds for ALT and bilirubin, but has progressive liver metastases and worsening liver tests before treatment began. What is the most appropriate conclusion?

The case is automatically a drug-induced Hy's Law case The laboratory findings should be ignored because cancer patients cannot develop DILI The findings represent a potential Hy's Law case requiring review, but the alternative disease explanation may substantially weaken drug causality The case should be classified as cholestatic solely because bilirubin is elevated

Question 3 of 10 Which sequence best represents a controlled aggregate DILI assessment process?

Regulatory action, then case identification, followed by laboratory collection Individual case identification, validation and classification, pattern analysis, signal conclusion and appropriate action or documented rationale R-ratio calculation followed immediately by product withdrawal Case report receipt followed by automatic confirmation of causality

Question 4 of 10 Which combination most directly indicates clinically important hepatic dysfunction rather than injury alone?

ALT elevation with normal bilirubin and INR ALP elevation without symptoms Jaundice with coagulopathy and possible encephalopathy Mild GGT elevation alone

Question 5 of 10 If viral investigations were not performed in a case with hepatocellular injury, which documentation is most accurate?

Viral hepatitis was excluded Viral hepatitis was absent because it was not reported Viral hepatitis was not fully evaluated, creating uncertainty in the causality assessment The case must be classified as definitely drug-induced

Question 6 of 10 Why does a substantial ALP elevation matter when evaluating a possible Hy's Law case?

It confirms a purely hepatocellular pattern It may indicate cholestasis or biliary obstruction, which can provide an alternative explanation for bilirubin elevation It makes bilirubin clinically irrelevant It proves that the injury is caused by a drug rather than disease

Question 7 of 10 What is the appropriate role of eDISH in clinical development?

It replaces individual medical review of liver-test abnormalities It identifies every case that is definitively caused by the investigational medicine It helps visualise and identify participants with potentially concerning ALT and bilirubin combinations for structured review It is a post-marketing case-processing requirement under EU GVP

Question 8 of 10 An inadvertent re-exposure is followed rapidly by a similar liver-test pattern to the initial event. What is the most appropriate interpretation?

The recurrence may provide strong causal evidence, subject to review of the re-exposure circumstances and phenotype The recurrence is irrelevant because rechallenge evidence is never usable The medicine is proven to cause all liver injuries in the treated population The event should be assessed only by its initial latency

Question 9 of 10 Which statement best describes the evidentiary status of a pharmacovigilance safety signal involving DILI?

A signal proves that the medicine caused the reported liver injuries A signal is a hypothesis requiring validation, analysis and prioritisation A signal requires immediate product withdrawal in every case A signal is equivalent to a confirmed adverse reaction

Question 10 of 10 A patient develops a marked ALT elevation during treatment, but bilirubin, INR and clinical status remain normal. Which interpretation is most appropriate?

The patient has hepatic failure because ALT directly measures liver function The result demonstrates drug causality if the ALT exceeds a predefined threshold The finding indicates hepatocellular injury but does not by itself establish hepatic dysfunction or drug causality The result is clinically irrelevant unless ALP is also elevated

QPPV.com

Drug-Induced Liver Injury (DILI): From Liver Test Abnormalities to Causality and Regulatory Safety Assessment

Cookie Settings